Press Releases

June 19th, 2019

HemoShear Therapeutics Names Biopharma Veteran Kathleen M. Metters, PhD, to Board of Directors

Read More »
March 20th, 2019

Takeda and HemoShear Therapeutics Extend Exclusive Drug Discovery Partnership in Liver Diseases

Read More »
March 6th, 2019

HemoShear Therapeutics Physiological Human Tumor Model Published in Lab on a Chip Journal

Read More »
January 3rd, 2019

Horizon Pharma Plc and HemoShear Therapeutics Enter Into Exclusive Drug Discovery Collaboration in Gout

Read More »
December 4th, 2018

Carnot Biosciences, A Spin Off Of Smartzyme Biopharma, And Hemoshear Therapeutics Partner To Develope Protein-Based Therapeutics For Rare Metabolic Diseases

Read More »
March 8th, 2018

HemoShear Therapeutics And Children’s National Rare Disease Institute To Present Data On Four Research Programs In Children’s Rare Diseases At The Society For Inherited Metabolic Disorders Meeting

Read More »
October 17th, 2017

Takeda and HemoShear Therapeutics Enter Into Exclusive Drug Discovery Partnership in Liver Diseases

Read More »
January 5th, 2017

HemoShear Therapeutics Appoints John E. Reardon As Head Of Research And Development

Read More »
December 20th, 2016

HemoShear Therapeutics Publishes Data In Journal Of Clinical Investigation Insight On Its Model Of Non-Alcoholic Steatohepatitis (NASH)

Read More »
November 9th, 2016

HemoShear Therapeutics To Present Data From Its Drug Discovery Platform For NASH At The American Association For The Study Of Liver Diseases Annual Meeting

Read More »
June 20th, 2016

UVA Health System And HemoShear Therapeutics To Collaborate On Advanced Cancer Tumor Models

Read More »
April 21st, 2016

Organic Acidemia Association Announces Funding Support To Develop Natural History Studies Of Diseases

Read More »
View More +

Contact

info@hemoshear.com

501 Locust Avenue
Suite 301
Charlottesville, Virginia 22902